Industry experts review specific study components which can be highly beneficial in terms of time and cost savings when included in a Phase 1/ First-in-Man clinical studies.
This week's Fierce LifeSci is brought to you by Frontage Laboratories.
Date: Thursday, November 12, 2020Time: 12pm ET / 9am PTDuration: 1 Hour
Phase 1 clinical program planning is complicated these days with added pressure to get maximum study data and move quickly to Phase 2 or partner the clinical asset. This presentation will review the following specific study components which can be highly beneficial in terms of time and cost savings when included in a Phase 1/ First-in-Man clinical studies:
Metabolites in Safety Testing (MIST) in SAD/ MAD studies
Concentration QT modeling (cQT modeling) in SAD studies
Time and cost-effective Dose Selection strategy for SAD studies, bridging preclinical data to First-in-Man and beyond
You are currently subscribed as newsletter@newslettercollector.com If you no longer wish to receive promotions from Fierce LifeSciences, simply unsubscribe. Refer to our Privacy Policy.
